Drug Trial Radar · NCT07843641
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Oct 13, 2026
Primary completion
Jan 31, 2031
Study completion Jan 31, 2031
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the long-term safety and tolerability of velzatinib (GSK6042981) in adults with GIST who have previously received velzatinib in parent study and continue to benefit from the treatment. Participants will be monitored for side effects and overall health to better understand the effects of long-term treatment and support future care for adults with GIST.
Conditions
- Gastrointestinal Neoplasms
Interventions
VelzatinibDrug
Velzatinib will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to 224 weeks
- Duration of TEAEs and SAEsTime frame: Up to 224 weeks
- Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) by severityTime frame: Up to 224 weeks
- Number of participants with adverse events or serious adverse events leading to dose modification or study intervention discontinuationTime frame: Up to 224 weeks
- Number of participants with clinically significant changes in vital signs, laboratory parameters, cardiac function, and Eastern Cooperative Oncology Group (ECOG) performance status changesTime frame: Up to 224 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.